Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib, Nivolumab, and Rituximab in Relapsed/Refractory Indolent Lymphoma
NCT04431635Phase 1Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Complete Response Rate at 1 year. Started Jun 2020; status: terminated.
02
Drugs
copanlisib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04431635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431635.